Literature DB >> 17910625

Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres.

David J Kuter1, Barbara Bain, Ghulam Mufti, Adam Bagg, Robert P Hasserjian.   

Abstract

In bone marrow biopsies, stromal structural fibres are detected by reticulin and trichrome stains, routine stains performed on bone marrow biopsy specimens in diagnostic laboratories. Increased reticulin staining (reticulin fibrosis) is associated with many benign and malignant conditions while increased trichrome staining (collagen fibrosis) is particularly prominent in late stages of severe myeloproliferative diseases or following tumour metastasis to the bone marrow. Recent evidence has shown that the amount of bone marrow reticulin staining often exhibits no correlation to disease severity, while the presence of type 1 collagen, as detected by trichrome staining, is often associated with more severe disease and a poorer prognosis. It was originally thought that increases in bone marrow stromal fibres themselves contributed to the haematopoietic abnormalities seen in certain diseases, but recent studies suggest that these increases are a result of underlying cellular abnormalities rather than a cause. A growing body of evidence suggests that increased deposition of bone marrow stromal fibres is mediated by transforming growth factor-beta and other factors elaborated by megakaryocytes, but it is likely that other cells, cytokines and growth factors are also involved. This suggests new avenues for investigation into the pathogenesis of various disorders associated with increased bone marrow stromal fibres.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17910625     DOI: 10.1111/j.1365-2141.2007.06807.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  74 in total

Review 1.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  Active thrombopoiesis is associated with worse severity and activity of chronic GVHD.

Authors:  T Bat; S M Steinberg; R Childs; K R Calvo; A J Barrett; M Battiwalla; K Baird; D Zhang; D Pulanic; C E Dunbar; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2013-07-08       Impact factor: 5.483

Review 3.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

4.  Quantitative analyses of myelofibrosis by determining hydroxyproline.

Authors:  Wanke Zhao; Wan-Ting Tina Ho; Zhizhuang Joe Zhao
Journal:  Stem Cell Investig       Date:  2015-01-26

5.  Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers.

Authors:  Sarah Farmer; Hanne Vestergaard; Stinus Hansen; Vikram Vinod Shanbhogue; Vikram Vinod Shanbhoque; Claudia Irene Stahlberg; Anne Pernille Hermann; Henrik Frederiksen
Journal:  Int J Hematol       Date:  2015-05-05       Impact factor: 2.490

Review 6.  PTH and stem cells.

Authors:  M Ohishi; E Schipani
Journal:  J Endocrinol Invest       Date:  2011-03-22       Impact factor: 4.256

7.  Myelodysplastic syndromes with bone marrow fibrosis.

Authors:  Matteo Giovanni Della Porta; Luca Malcovati
Journal:  Haematologica       Date:  2011-02       Impact factor: 9.941

8.  Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.

Authors:  Waleed Ghanima; Julia Turbiner Geyer; Christina S Lee; Leonardo Boiocchi; Allison A Imahiyerobo; Attilio Orazi; James B Bussel
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

9.  Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.

Authors:  Oliver Bock; Julia Höftmann; Katharina Theophile; Kais Hussein; Birgitt Wiese; Jerome Schlué; Hans Kreipe
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

10.  Treatment of immune thrombocytopenic purpura: focus on eltrombopag.

Authors:  Lawrence Rice
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.